Emerging Medical Therapy in Eosinophilic Esophagitis

This article will highlight the most up-to date literature for emerging medical therapy for this disease.Recent findingsIt is estimated that nearly one-third of patients with eosinophilic esophagitis will not respond to traditional pharmacologic therapies which include proton-pump inhibitors and swallowed topical corticosteroids. The need for more effective therapy has led to an explosion of research for targeted biologic therapies, and there are several promising molecules in the pipeline.SummaryA number of Phase II and III clinical trials are underway and show propitious results for treatment in eosinophilic esophagitis. In 2022, the Food and Drug Administration approved the first treatment for eosinophilic esophagitis, dupilumab. This approval satisfies an unmet need for a growing number of patients with eosinophilic esophagitis. It is likely that in the future, there will be multiple therapeutic options for the management of eosinophilic esophagitis.
Source: Current Treatment Options in Gastroenterology - Category: Gastroenterology Source Type: research